UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~March 129, 2026

COHERUS ONCOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-36721		27-3615821
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

333 Twin Dolphin Drive, Suite 600

Redwood City, CA 94065

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (650) 649-3530

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		CHRS		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

OnItem ~~February 12, 2026, Coherus Oncology, Inc~~2.02 ~~(the~~Results “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Oppenheimer & Co. Inc. as representatives (the “Representatives”) of ~~the~~Operations ~~several underwriters named therein (collectively, the “Underwriters”), pursuant to which the Company agreed to issue~~ and ~~sell~~Financial ~~an aggregate of 28,600,000 shares (the “Firm Shares”) of its common stock, par value $0~~Conditions.0001 per share (“Common Stock”) to the Underwriters (the “Offering”). Additionally, under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, for 30 days from the date of the Underwriting Agreement, solely for the purpose of covering over-allotments, if any, to purchase up to an additional 4,290,000 shares of Common Stock (the “Optional Shares,” and together with the Firm Shares, the “Shares”). The price to the public in the Offering was $1.75 per share. The Underwriters agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $1.645 per share.

~~The~~On ~~Offering~~March ~~was~~9, ~~made~~2026, ~~under~~Coherus Oncology, Inc. (the “Company”) issued a ~~prospectus~~press ~~supplement~~release ~~and~~regarding ~~related~~its ~~prospectus~~financial ~~filed~~results ~~with~~for the ~~Securities~~quarter and ~~Exchange~~fiscal ~~Commission~~year ~~pursuant~~ended toDecember ~~the~~31, ~~Company’s~~2025. ~~effective~~The ~~shelf~~full ~~registration~~text ~~statement~~of onthe ~~Form~~press ~~S-3~~release ~~(Registration~~is Nofurnished as Exhibit 99. ~~333~~1 to this Form 8-~~291520)~~K.

OnThis ~~February~~information ~~17,~~in ~~2026,~~this Item 2.02 of this Form 8-K and the ~~Company~~Exhibit ~~completed~~99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the ~~sale~~Securities and ~~issuance~~Exchange Act of an1934, ~~aggregate~~as ofamended 28(the “Exchange Act”),~~600,000~~ ~~shares~~or otherwise subject to the liabilities of ~~Common~~that ~~Stock.~~Section, ~~The~~or ~~Company~~incorporated ~~received~~by ~~net~~reference ~~proceeds~~in ofany ~~approximately~~filing ~~$47.0~~under ~~million~~the Securities Act of 1933, ~~after~~as ~~deducting~~amended, or the ~~Underwriters’~~Exchange ~~discounts~~Act, ~~and~~except ~~commissions~~as ~~but~~shall ~~before~~be ~~estimated~~expressly ~~offering~~set ~~expenses~~forth ~~payable~~ by ~~the~~specific ~~Company.~~reference in such a filing.

The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. The Company and the Company’s directors, executive officers and certain stockholders that are affiliated with the Company’s directors also agreed not to sell or transfer any Common Stock for 60 days after February 12, 2026, without first obtaining the written consent of the Representatives, subject to certain exceptions as described in the prospectus supplement.

A copy of the Underwriting Agreement, including the form of lock-up agreement, is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing descriptions of the Underwriting Agreement and lock-up agreements are not complete descriptions thereof, and are qualified in their entirety by reference to such exhibit.

A copy of the opinion of Latham & Watkins LLP relating to the validity of the securities issued in the Offering is filed herewith as Exhibit 5.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits .

Exhibit No.		Description
1.1		Underwriting Agreement, dated as of February 12, 2026, among Coherus Oncology, Inc. and TD Securities (USA) LLC, Guggenheim Securities, LLC and Oppenheimer & Co. Inc., as representatives of the several underwriters named therein
5.1		Opinion of Latham & Watkins LLP

23.1		Consent of Latham & Watkins LLP (included in Exhibit 5.1)

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)


Exhibit No.		Description

99.1		Press release dated March 9, 2026.

104		Cover page Interactive Data file (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: February 17, 2026	COHERUS ONCOLOGY, INC.
Date: March 9, 2026	COHERUS ONCOLOGY, INC.

	By:	/s/ Dennis M. Lanfear
	Name:	Dennis M. Lanfear
	Title:	Chief Executive Officer

Filing Compare · Coherus Oncology, Inc.